These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 8912629)

  • 1. Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors.
    Onishi Y; Kizaki H
    Biochem Biophys Res Commun; 1996 Nov; 228(1):7-13. PubMed ID: 8912629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
    Kizaki H; Onishi Y
    Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.
    Horiguchi-Yamada J; Fukumi S; Saito S; Nakayama R; Iwase S; Yamada H
    Anticancer Res; 2002; 22(6C):3827-32. PubMed ID: 12553001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
    Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
    Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
    Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
    Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
    Yu Q; Mirski SE; Sparks KE; Cole SP
    Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.
    Mattern MR; Mong SM; Bartus HF; Mirabelli CK; Crooke ST; Johnson RK
    Cancer Res; 1987 Apr; 47(7):1793-8. PubMed ID: 3028614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
    Kuo CC; Liu JF; Chang JY
    J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
    Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
    Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
    Muscarella DE; Rachlinski MK; Sotiriadis J; Bloom SE
    Exp Cell Res; 1998 Jan; 238(1):155-67. PubMed ID: 9457068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, topoisomerase I inhibitory activity and in vitro cytotoxicity of camptothecin derivatives bearing five-membered heterocycle containing 10-substituents.
    Zhao R; Guan LL; Oreski B; Lown JW
    Anticancer Drug Des; 1998 Mar; 13(2):145-57. PubMed ID: 9524556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of topoisomerase II inhibitor, vepesid, on binding of doxorubicin with DNA in tumor cells sensitive to anthracycline].
    Bogush TA; Chmutin EF; Syrkin AB
    Biull Eksp Biol Med; 1997 Jan; 123(1):87-90. PubMed ID: 9213469
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
    Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.